Immunisation Update

Dr. Anna Clarke

Consultant in Public Health Medicine Health Service Executive National Immunisation Office

May 2015





Learning Objectives

Principles of immunisation Childhood immunisation schedule in Ireland Some Individual Vaccines Uptake Rates NEW Schedule Resources





Why Immunise?

- Immunisation is one of the most effective and safest of all health interventions
- Immunisation has saved more lives than any other public health intervention apart from the provision of clean water





What is Immunisation?

- The process of artificially inducing immunity or protection from disease
- Active
 - Administration of a vaccine or toxoid in order to stimulate antibody production or other immune responses e.g. Inactivated (Hib), Attenuated live (MMR, BCG) or toxoid (Tetanus, Diphtheria)

Passive

 The administration of preformed antibodies in order to provide temporary immunity e.g. HNIG or specific immunoglobulins





Aim of Immunisation

• To reduce the incidence of or to eliminate a particular disease

Direct and indirect effect

- "Herd Immunity"-indirect effect-reduction in the incidence of disease in population
- Consider individual risk of vaccine versus society benefit of herd immunity





Live vaccines

- Attenuated (weakened) viruses
 /bacteria
- Produces long lasting immune response after one or two doses

e.g. BCG/ MMR/ Varicella/ Yellow fever





Inactivated (killed) vaccines and toxoids

- Cannot cause disease they are designed to protect against
- Two or more doses plus booster doses usually required

e.g. Influenza/Diphtheria/Tetanus/ Hepatitis B





General Contraindications to Immunisation

- Anaphylaxis to a previous dose of any vaccine or one of its constituents or a constituent of the syringe, syringe cap or vial (e.g. latex anaphylaxis)
- Live vaccines and immunosuppression e.g. MMR, BCG
- Live vaccines and pregnancy
- Postpone immunisation if acute severe febrile
 illness





Conditions which are not Contraindications

- FHx of adverse reactions
- Minor infections
- FHx of convulsions
- Hx of pertussis, measles, rubella or mumps in the absence of proof of immunity
- Prematurity or LBW
- Stable neurological conditions e.g. CP
- Contact with an infectious disease

- Asthma, eczema, hayfever, migraine, food allergy
- Therapy with antibiotics
- Child's mother pregnant
- Child's being breastfed
 - Hx neonatal jaundice
- Child over recommended age
- Low dose methotrexate, azathioprine or 6-mercaptopurine
- Recent/imminent surgery
- Corticosteroid therapy
- Non anaphylactic allergy





Precautions

- All vaccines
 Moderate/severe illness-defer until recovery unless the benefits outweigh the risks
- Stop topical immunomodulators 28 days before live vaccines and do not restart for 28 days.
 No issue with inactivated vaccines
- Live viral vaccines and immunoglobulins -Immune response inhibited. Leave interval





Immunisation Successes

- Meningococcal C Campaign (Reduced incidence of cases by 90% since October 2000)
- Eradication of smallpox
- ? Near eradication of poliomyelitis
- Control of others, e.g. Hib, diphtheria, pertussis??
- Successful immunisation more attention to vaccine related illness







Current Primary Childhood Immunisation Schedule

- Birth-1month
- 2 months
- 4 months
- 6 months
- 12 months
- 13 Months

6 in 1 + PCV

BCG

- 6 in 1 + Men C
- 6 in 1 + Men C + PCV
- MMR + PCV
- Hib + Men C

PCV 7 introduced in September 2008 PCV13 introduced in December 2010





Poliomyelitis



Feidhmeannacht na Seirbhise Sláimte Health Service Executive

Poliomyelitis

- Caused by polio virus
- Incubation period 3-21 days
- Mode of Transmission Oro-faecal
- Clincal Description

Acute illness Invades nervous tissues – paralysis Highly infectious


Mainly affects children under 5








Polio cases notified 1948-2014









¹cVDPV is associated with \ge 2 AFP cases or non-household contacts. VDPV2 cases with \ge 6 (\ge 10 for type1) nucleotides difference from Sabin in VP1 are reported here. ²Excludes viruses detected from environmental surveillance.

Data in WHO HQ as of 21 April 2015

Poliomyelitis vaccines

- 2 months
- 4 months
- 6 months
- **4-5** years

6 in 1 + PCV

- 6 in 1 + Men C
- 6 in 1 + Men C + PCV
- DTaP/IPV

Fully immunised persons at increased risk of exposure

Fully vaccinated persons aged 10 years and over at increased risk of exposure to wild poliovirus should be given a single dose of Tdap/IPV





Vaccination

Contraindications

Anaphylaxis to any of the vaccine components

Precautions

- Acute febrile illness defer
- Arthrus-type reaction. Should not receive further routine or emergency booster doses more frequently than every 10 years
- Adverse reactions
 - Local reactions
 - General





Pertussis



Feidhmeannacht na Seirbhíse Sláime Health Service Executive

Pertussis (Whooping Cough)

- Caused by Bordetella Pertussis
- Incubation period 6-20 days (typically 5-10 days)
- Mode of Transmission
 - Respiratory Droplets
- Clinical description

 Cough
- Most dangerous in children <1
- Infectious baby
- Can last for months






Pertussis Pertussis vaccine introduced, 1952/53 6000 Number of cases notified 5000 CHTIM 4000 3000 DTaP vaccine Pertussis vaccine scare mid TdaP vaccine Introduced, 1996 2000 1970s Introduced, 2011/2012* 1000 0 1956 1960 1976 2008 1948 1952 1964 1968 1972 1980 1988 1992 1998 2000 2012 1984 2004 Year

*An adolescent pertussis booster was introduced into the school programme (in 19 LHOs) in 2011 and to all schools in 2012. In August 2012, an additional pertussis booster was recommended for health care workers and pregnant women Data were extracted from CIDR 11/09/2014. 2014 data are incomplete and provisional. OTECTHE



Pertussis Notifications 2012-2015




Courtesy of HPSC





Pertussis notifications by age group and year 2012-2015



Courtesy of HPSC





Pertussis Vaccines

- Primary as part of 6 in 1 at 2,4,6, months
- Booster aged 4-5 -as part of a 4 in 1 vaccine (DTaP/IPV)
- Booster aged 11-14 years as part of a Tdap vaccine

- HCW additional booster doses recommended for those in contact with young children (neonatal, paediatrics, delivery), antenatal and postnatal pregnant women, and immunocompromised (oncology, haematology), renal dialysis and ICU staff, general practice staff
- Pregnant Women 27-36 weeks gestation each pregnancy
- Adults every 10 years if they want to protect themselves and young children

A MUNIS



Pertussis Vaccine

 Acellular vaccine less adverse reactions than whole cell vaccine

Contra-indication

- Anaphylaxis to any of the vaccine components

- Precautions
 - Acute severe febrile illness; defer until recovery





MMR





Why is MMR so Important?

Protects children against contracting measles, mumps and rubella

- Individual protection
- Population protection
- Potential eradication of the diseases

Two doses of MMR

Immunity against measles in 99% of vaccinees
 Immunity against mumps in 88% of vaccinees
 Immunity against rubella in 95% of vaccinees





Measles USA


Measles Cases and Outbreaks January 1 to April 3, 2015*



reported in 18 states and the District of Columbia: Arizona, California, Colorado, Delaware, Georgia, Illinois, Michigan, Minnesota, Nebraska, New Jersey, New York, Nevada, Oklahoma, Pennsylvania, South Dakota, Texas, Utah, Washington

representing 91% of reported cases this year

Outbreaks



Majority unvaccinated and many imported





Measles USA 2015

117 cases linked to measles outbreak74% of all cases reported in 2015Index case- unvaccinated 11 year old

- rash onset December 2014

24 million visitors annually



ple visit Disneyland on January 22, 2015 in Anaheim, California. File photo by Frederic J. Brown/AFP





Measles EU March 2014 – February 2015


- 3760 cases reported
- 30 countries
- Italy, Germany and France
- Majority of cases not vaccinated (75%)
- 6 cases of encephalitis







Measles Events Ireland 2013 -2015




Courtesy of HPSC






Mumps Events Ireland 2013-2015



Courtesy of HPSC







Mumps Events by Age Group and Case Classification

Courtesy of HPSC





Schedule for MMR

Second Dose → 4-5 years as part of school entry vaccination

≻ Live virus vaccine with immunity to
 ≻ Measles → 6-11 days
 > Rubella → 10-15 days
 > Mumps → 15-21 days





Measles/Mumps/Rubella

- Live vaccine-safe and effective
- In outbreak situation-MMR can be given to children at 6 months of age
- No evidence to support any link between MMR vaccine and the subsequent development of either inflammatory bowel disease or autism
- Egg allergy even anaphylaxis **IS NOT** a contraindication to MMR Vaccine.





Measles/Mumps/Rubella

Contraindications include:

- Hx of anaphylaxis to a previous dose of MMR or one of its constituents e.g Neomycin and Gelatin
- Significantly immunocompromised persons -Untreated malignant disease and immunodeficiency states other than HIV, and those receiving immunosuppressive therapy, high dose x-ray therapy and current high-dose steroids
- Pregnancy. Furthermore, pregnancy should be avoided for one month after MMR immunisation





Measles/Mumps/Rubella

Precautions

- Moderate/serious illness. Postpone until recovered
- Injection with other live vaccine within previous 4 weeks
- Injection of immunoglobulin, whole blood or any antibody-containing blood product within the previous 3-11 months
- Topical Tacrolimus and other immunomodulators shoould be deferred for 28 days before and after the administration of MMR vaccine
- Patients who develop thrombocytopenia within six weeks of 1st dose of MMR should undergo serological testing to decide whether 2nd dose is necessary. 2nd dose recommended if not fully immune






Primary Immunisation Uptake Rates






Vaccine uptake rate at 24 months 1999-2014




Quarter 3 2014 D3 immunisation uptake rates (%) by LHO, in those 24 months of age in Ireland and Dublin (source HPSC)







Quarter 3 2014 MMR immunisation uptake rates (%) by LHO, in those 24 months of age in Ireland and Dublin (source HPSC)









Decline in vaccine uptakes

Quarter 3 2014 Men C₃ immunisation uptake rates (%) by LHO, in those 24 months of age in Ireland and Dublin (source HPSC)








Feidhmeannacht na Scirbhise Sláimt Health Service Executive

Decline in vaccine uptakes

Actions

- Highlight 5 visits at every opportunity
- Give an appointment for next visit
- Send a text reminder before appointment
- Follow up defaulters as soon as possible
- Send vaccine returns on time
- Defaulters need appropriate vaccines even if they are over the recommended age







New Primary Childhood Immunisation Schedule for Babies born on or after 1st July 2015

Age	Immunisations	Comment
Birth	BCG	1 injection
2 months	6 in 1 + PCV	2 injections
4 months	6 in 1 + MenC	2 injections
6 months	6 in 1 + PCV	2 injections
12 months	MMR + PCV	2 injections
13 months	MenC + Hib	2 injections





New PCI schedule July 1st 2015

NEW

- Guidelines for Vaccinations in General Practice
- Frequently asked questions
- Information booklet Your Child's Immunisation
- Passports
- Posters
- Fridge magnets

To be delivered to all GPs in June 2015



Feidhmeannacht na Seirbhíse Sláime Health Service Executive

NIAC recommendations

	Recommendation	Implementation
MenC* (Aug 2014)	Schedule change from 4,6 and 13 months to 4,13 months	July 1 st 2015
	Introduction of adolescent dose at 12-13 years	2014/2015
Rotavirus (2013)	Oral vaccine recommended 2 -3 doses at 2, 4 and 6 months	??
MenB (Jan 2015)	Introduction to PCI schedule	??

* MenC

- Evidence 1 dose is sufficient in infants
- Same schedule introduced in the UK in 2013








Rotavirus - Ireland

Figure 19.1. Number of cases of rotavirus by year, 2004 to 2012 (Source:HPSC)








Rotavirus - Ireland









Rotavirus vaccine

- Recommended by WHO
- Implemented in USA, UK + 8 other EU countries
- Recommended by NIAC
- Live oral vaccine
- 2-3 doses at 2,4 or 2,4, 6 months
- Can be given at same time as other vaccines
- All doses by 8 months of age
- Small increase in intussusception (benefits >>>risks)
- Recent European study
 - vaccine effectiveness 68% to 98%
 - 65% to 84% reduction in rotavirus hospitalisations








New vaccines

- Meningococcal Group B
 - licensed
 - recommended for contacts
 - and
 - at risk groups
 - NIAC recommendation for universal vaccination ?? date for implementation



TD calls for

vaccine deal

brain bug



By Kevin Keane


HEALTH campaigners have called on the Department of Health to follow the lead of authorities in Britain and the North by making a new vaccine introduction of the vaccine if a cost-effective agreement can be reached with the manufacturer.

Dependent on deal with drug's maker





No. of IMD cases notified in Ireland by serogroup by year - HPSC







New vaccines

- Meningococcal Group B
 - can be given to healthy children
 - dosage schedule and further details in Immunisation Guidelines

http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf

- due to an increased risk of fever, local reactions, change in eating habits and irritability when MenB vaccine is given with other vaccines it may be preferable to administer this vaccine with an interval of 1 week before or after other vaccines.
- consider prophylactic paracetamol at the time or shortly after vaccine for children under 2 years
- Vaccine supply and more details from Allphar 01 4688456.





HPV 9 vaccine

- 5 additional oncogenic HPV types (31,33,45,52,58)
- 97% effective in preventing high-grade lesions of the cervix, vagina and vulva
- Generally well tolerated
- Expect vaccine to protect against infection and diseases caused by 9 HPV types
 (80-90% of the cancers, high grade lesions and genital warts caused by HPV)
- Licensed in US (3 dose schedule)
- Due to be licensed in EU in 2015






Adolescent MenC booster vaccine UK

- MenC adolescent booster introduced in 2013
- Cases of Men W increased from 22 cases in 2009 to 117 in 2014
- Not travel related

March 2015

- JCVI recommended Men ACWY for 14-18 year olds (routine + catch up)
- Likely to be introduced in 2015/2016

No increase in Men W cases in Ireland



Number of laboratory confirmed cases of MenW disease and associated deaths by age group and year of diagnosis over six epidemiological years in England and Wales. <u>http://cid.oxfordjournals.org/content/early/2014/</u> 1/10/cid.ciu.921 obstract

1/10/cid.ciu881.abstract




0



GP Guidelines

- Roles and responsibilities
- Procedures
- Adverse events
- Common issue
- Cold chain maintenance
- Currently being updated







More information




February 2015 **National Immunisation News** The newsletter of the HSE National Immunisation Office **Changes to the Primary Childhood Immunisation Programme** CONTENTS The National Immunisation Advisory Committee (NIAC) has recommended changing the meningococcalC (MenC) immunisation schedule in the primary childhood programme from three doses at 4.6 Changes to the PCI programme and 13 months to two doses at 4 and 13 months because of evidence Uptake statistics that a single dose of MenC vaccine provides protection for the first year Pneumovax name change of life. Flu season Common queries This new primary childhood immunisation schedule will be introduced School Immunisation System for all babies born on or after July 1st 2015. Further details and new Ordering online information materials for the Primary Childhood Immunisation Cold chain breach Programme are being developed. Vaccine list Primary Childhood Immunisation Schedule Preparing vaccines CURRENT SCHEDULE NEW S Contact information ate of birt Babies born up to 30° June 2015 1"Jub Age nmunisations Comment nmunisations Comment 6 in 1 + PCV 2 months 2 injections 2 injection 6 in 1 + Men 6 in 1 + Men0 2 injection 6 months 3 injection: Æ Ment MMR + PCV MMR + PCV 2 injections 2 injections MenC + Hil MenC + Hit Feidhmeannacht na Seirbhíse Sláinte Health Service Executive PCV nococcal conjugate vacine reococcalCvaccin s, Mumps, Rubel www.immunisation.ie Please continue to use the current primary childhood schedule.

http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html









Acknowledgements



National Immunisation Office



Feidhmeannacht na Seirbhíse Sláinte Health Service Executive



- National Immunisation Office www.immunisation.ie
- Health Protection Surveillance Centre www.hpsc.ie
- Immunisation Guidelines for Ireland. On line only http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines//

Immunisation schedules

- World Health Organisation. http://apps.who.int/immunization_monitoring/globalsummary/schedules
- Europe. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
- MMR Series Deer B. *BMJ* 2011; 342:c5347





Useful Resources

- Health Products Regulatory Authority www.hpra.ie
- American Academy of Paediatrics. 2012 Report of the Committee on Infectious Diseases – The Red Book. http://aapredbook.aappublications.org/
- Department of Health UK. November 2013. Immunisation against infectious disease. https://www.gov.uk/government/uploads/system/uploads/attachment __data/file/266583/The_Green_book_front_cover_and_contents_pag e_December_2013.pdf
- Public Health England Infectious Diseases
 https://www.gov.uk/health-protection/infectious-diseases
- World Health Organisation. Adverse events following immunisation http://www.who.int/immunization_safety/aefi/en/



